Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elixinol to acquire 25% equity interest in Pet Releaf,the market leading US-based CBD pet products company
https://www.elixinolglobal.com/site/PDF/2438_0/Elixinolacquires25ofUSbasedPetReleaf
Solid quarter, plenty of cash, scaled back private label (which they were simply creating their own competitors) to focus more on building their own brand. Grow operations in Australia on track, recyclable/biodegradable hemp plastic in the works.....Onward Ellxf
"Elixinol Ltd results: Why this ASX pot stock dropped today"
https://www.fool.com.au/2019/04/23/elixinol-ltd-results-why-this-asx-pot-stock-dropped-today/
Lachlan Hall | April 23, 2019 | More on: EXL
The Elixinol Ltd (ASX: EXL) share price has fallen 2% this morning as investors had a mixed reaction to the company’s March 2019 quarterly results.
What did Elixinol announce this morning?
Elixinol reported Q1 2019 group revenue of $8.2 million, representing a 21% increase on the prior corresponding period (pcp) and a 31% quarter-on-quarter (QoQ) decline.
Management attributed the QoQ decline to the company’s decision to reduce the focus on low margin private label business in the US to enable increased capacity for the expected growth of higher margin branded products and provide the ability to capture further market share.
Elixinol reported a strong financial position and a healthy balance sheet with $27.4 million in cash as at quarter end with US retail broker Presence Marketing appointed to help it reach into more than 15,000 retail stores.
The company’s regional highlights included the commencement of US national distribution sales beginning Q2 2019 following an initial order for 13 Elixinol branded CBD topical and dietary supplement products from a large ‘bricks and mortar’ national retailer initially across 330 stores with expectations of a rollout to more than 1,000 stores.
The industrial hemp and emerging medicinal cannabis company also reached a European promotional partnership agreement with Cambrian Alliance Group (UK) and received a purchase order for distribution in a popular UK high-end retailer among other ongoing conversations.
What’s been happening to the Elixinol share price?
The Elixinol share price has rocketed 85.5% so far this year to $4.99 per share amid solid earnings and strong growth prospects for the company and sector as a whole.
With a market cap of $621.5 million, Elixinol is no small player in the growing cannabis sector despite this morning’s early volatility.
Since January 2018, the company’s share price has nearly trebled in what has been a real outperformer on the ASX in recent times.
I’m reasonably bullish on the stock in the long-term despite the potential regulatory headwinds and I would expect the stock to soar higher if a Labor government is elected in the May Federal Election.
For those who want to look at other options within the hemp and cannabis sector, this top-rated stock could be another great option for Fools looking to improve portfolio gains in 2019.
One ASX Stock For An Estimated $US22 Billion Marijuana Market
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Either would be huge let’s hope for both
Bought the land for Nunyara - 60 acres.
I wonder if its CVS? Walgreens etc that they are referring to as the brocks and mortar stores in the US?
The price will hold up just fine.
Looks like you are wrong in your price predictions.
So, basically:
-31% revenue decline QoQ
-Dramatically increased inventory in anticipation of an expected increase in consumer demand
-Improved balance sheet from Q4 (IIRC), cash of 27.4m
-Signed an agreement with Presence Marketing to gain shelf placement and support product sales on an ongoing basis throughout the US.
-Partnered with Multiply, "a nationally recognised PR and Analytics Agency"
-Received an order for 13 SKUs from a large brick and mortar national retailer initially across 330 stores; expecting a rollout to over 1000 US stores
In the UK:
-Reached an agreement with Cambrian Alliance Group, which has over 1200 member pharmacies, rollout commenced in April
-Entered into a sales and distribution agreement with a major distributor; they received a purchase order for 60,000 units of 6 SKUs for distribution across 250 stores
In AU:
-Still no update on licensing for Nunyara
They justify the revenue decrease as "driven by Elixinol’s strategic decision to reduce focus on low margin private label business in the US to enable increased capacity for expected future growth of higher margin branded products and provide the ability to capture further market share."
Don't know how much of the distribution news is new, but tomorrow is likely to be a decline. EXL currently down over 3%.
https://www.elixinolglobal.com/site/PDF/2436_0/QuarterlyReportandAppendix4C
1st quarter financials
A bunch of notices out on the upcoming Annual General Meeting on May 23rd insert-text-here
This looks great!
Text from ELLXF PR
Elixinol and KBMD Health Launch New Hemp CBD Extract
By GlobeNewswire, April 17, 2019, 12:00:00 PM EDT
Leading Hemp-Derived CBD Brand Partners with Renowned Gastroenterologist to Create Product Intended to Alleviate Abdominal Discomfort
DENVER, April 17, 2019 (GLOBE NEWSWIRE) -- Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, announces its latest product in partnership with Ken Brown, MD of KBMD Health, KBMD CBD Extract in Elixinol's signature Natural and Cinnamint flavors. Created in partnership with Dr. Brown, an established physician specializing in gastroenterology, this full-spectrum product contains 900mg of CBD in a 1oz tincture, and is intended to help alleviate abdominal discomfort caused by inflammation in those impacted by digestive issues.
Passionate about bridging the gap between natural and medical science, Dr. Brown has been utilizing Elixinol hemp CBD extract for over two years in his own gastroenterology practice to support the digestive wellness of hundreds of patients. Dr. Brown indicates that his patients typically report feeling relief when consuming a daily serving size of 30mg (15mg twice per day).
"Elixinol's hemp CBD extracts have proven to be instrumental to my patients in alleviating abdominal discomfort caused by digestive issues," said Dr. Brown. "I've been able to identify that a daily serving size of 30mg of CBD, paired at times with their current therapies, helps to relieve GI distress and control chronic illnesses with inflammatory flare ups. Elixinol's dedication to quality, third-party tested CBD products, as well as clean sourcing, extraction and production processes, made it an easy decision in terms of a partner for this product."
"Elixinol is proud to partner with KBMD Health to produce this hemp CBD extract," said Chris Husong, VP of Marketing and Communications at Elixinol. "Specialists like Dr. Brown who've identified a hyper-specific need are going to help us pave the way for the future of the quickly growing and evolving CBD industry. He's helping those who are newer to the world of cannabinoids understand the vast potential for daily health and wellness."
KBMD Hemp CBD Extract is available at https://kbmdhealth.com/900mg-kbmd-cbd/ for a suggested retail price of $89.99 in Elixinol's signature Natural and Cinnamint flavors.
About Elixinol
Colorado-based Elixinol, co-founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting premium-quality hemp, Elixinol is one of the few CBD hemp extract brands with complete seed-to-sale control over its products. Elixinol also conducts rigorous third-party laboratory testing and quality control. Elixinol distributes hemp-derived CBD products in 40 countries globally including North and South America, throughout Europe, Asia, and the Pacific Region under its own label as well as bulk CBD and wholesale CBD. Elixinol is a wholly owned subsidiary of Elixinol Global (EXL) (elixinolglobal.com) which is publicly traded on the Australian Securities Exchange and on the U.S. OTC (ASX:EXL, OTCQX:ELLXF). More information available at Elixinol.com.
About KBMD Health
Dr. Ken Brown is a renowned physician in the gastroenterology field passionate about "bridging the gap" between medical and natural sciences. Truly believing that learning doesn't stop once a Doctorate is achieved, Dr. Brown started a clinical research effort over a decade ago in order to uncover new and innovative approaches to health and wellness. In addition to the KBMD 900mg Natural CBD Extracts he partnered with Elixinol on, Dr. Brown created Atrantil Capsules, geared to relieve symptoms of bloating and abdominal discomfort with a natural approach using polyphenols. Dr. Brown has been featured in many top-tier publications, multiple TV platforms, and several podcasts. He has recently launched the "Gut Check Project" digital radio show and podcast where he hosts great guests to talk health, science, and more on his expertise and mission. More information available at KBMDHealth.com.
Media Contacts:
Blythe Tokar
+1 202-292-4573
elixinol@wearemultip.ly
Chris Husong
Elixinol
+1 844-804-3504 ext 420
chris@elixinol.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/50b95c38-32ee-4213-b912-ff0458b5e35d
Source: Elixinol LLC
This article appears in: News Headlines
Referenced Stocks: ELLXF
Awesome. If this move holds I think we have a bottom here. Multi week/month bottom
Doubtful. Just A fly by nighter who trolls serious investors and traders while touting junk like MJNA.
They still doing that affiliate multi level marketing crap? They’re (MJNA) doomed to fail, unlike Elixinol, a pretty clear winner in the cbd sector.
So I guess you are a short? lol
Elixinol Global Ltd. $ELLXF Book Value ONLY $.71 Too expensive
Management Effectiveness
Return on Assets (ttm) -0.46%
Return on Equity (ttm) -0.71%
Profitability
Profit Margin -2.32%
Operating Margin (ttm) 0.00%
https://finance.yahoo.com/quote/ELLXF/key-statistics?p=ELLXF
That would be sweeeet!
I trade with E-Trade and this news about the certification isn't published. I think it should be.
Excellent! US Hemp Authority Certification!
Yesssssss...Charlotte's web is going to buy them out. .
Make sure you stick to your plan and what works for you..
Decided to grab half of ELLXF, it has significant drop from the top as well percentage wise..
Gltu
yeah, sometimes i get them too early, sometimes not so bad. but definitely partial size to start. but i think i'm far enough down in that daily range. half size was really reserved for incase it fell to 17s, which i was eyin those feb highs. daily definitely has oscillated to buy so somewhere down in here. intraday holding decently
I got the point of adding and adding .. of you start adding too early..
I always look up retracing waves by Fibonacci and if I use 25.25 for top and 13.5 for bottom.. 62% retracement is 18 +/-.. Nice bounce from this level should be in cards UNLESS we get more selling pressure from overall sector.
Sometime you also have to have strong balls to play this game and buy in when everyone else is panicking.
Also Pivot point for Charlotte’s on hourly in US $ is 17.99.. if 18s break, then MA50 would be next add.. Unfortunately
Good luck to us!
I have a bid here also at ELLXF.. no fill yet
i think (hoping) that if we can get a pop through 19.30s that any dip from there should be in play for sure. and if it closes near fridays close we should have a reversal on our hands.
one of my least favorite things to do though is add and add to a falling knife. been burned doing that before; will never again
I have to admit that I don't see strength yet but decided to take a risk and add only because it bounced from low 18s before a couple of times on a chart ..
If selling pressure in the sector continues than my short term pile is going to be red and I will have to add lower to keep it balanced..
i'm restricted to 1 post on the other board. gonna see if she can act right before adding other half. 60 min just is telling me capitulation here but still no strength yet. bottom/reversal for me should be seen through 19s for confirmation of idea. if 5min can pop a bit more we'll have some positive divergence on intraday charts
I do think FDA interim negativity will lead the price down for a while, til regulations become clear. Not sure if what we are seeing is a pullback or a trend reversal.
ELLXF very predictable. That was a sweet flip opportunity.
OK, gaps closed. Chart looking good again
Let's close that one more gamp so we could move forward again
they will turn on a dime and dig for nickel's ...
Mitch McConnell has been pushing hard for hemp because his state Kentucky is going to make nice $ from hemp farming. He knows it.
.. and yet he approved Epidiolex as a drug (which is pure CBD) last year ? Ha! Classic BS statement.
General article on CBD: insert-text-here
They’re buying cbd stocks as well. It’s not a coincidence that republicans are the ones to push it forward.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |